ANDA Backlog Fee Non-Payment: FDA Will Weigh Fairness Vs. Public Health

FDA may have more than one set of rules to determine whether it will approve a backlogged generic drug if the sponsor does not pay the one-time backlog fee created by the agency/industry agreement on generic drug user fees.